SCHEMBL692818

SCHEMBL692818

O=c1[nH]cccc1O.[Fe]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82455 0.97
SCHEMBL9517333 0.95
Ammonia Solution, Strong SCHEMBL17005900 0.95
SCHEMBL30482581 0.95
SCHEMBL4286239 0.95
SCHEMBL5596103 0.95
SCHEMBL29127320 0.95
Naphthalene SCHEMBL11343213 0.89 DAO (0.83)
Carbamic Acid SCHEMBL8959472 0.87 DAO (0.79)
Formamide SCHEMBL28332093 0.87 DAO (0.79)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2299265-A1 Cancer eradication program Signe BioPharma Inc. (US) 2011-03-23 EP claimed
US-20100278729-A9 BREAST CANCER ERADICATION PROGRAM SIGNE BIOPHARMA INC. (US) 2010-11-04 US claimed
US-20080226549-A1 BREAST CANCER ERADICATION PROGRAM SIGNE BIOPHARMA INC. (US) 2008-09-18 US claimed
EP-1827419-A2 METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION Drugtech Corporation (US) 2007-09-05 EP claimed
WO-2006068729-A2 METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION DRUGTECH CORPORATION (US) 2006-06-29 WO claimed
US-20060134227-A1 Compositions including iron DRUGTECH CORPORATION 2006-06-22 US claimed
EP-1530720-A4 BREAST CANCER ERADICATION PROGRAM SIRBASKU DAVID A (US) 2005-08-31 EP claimed
EP-1530720-A2 BREAST CANCER ERADICATION PROGRAM Sirbasku, David A. (US) 2005-05-18 EP claimed
WO-2003086321-A2 MODIFIED RELEASE MINERALS DRUGTECH CORPORATION (US) 2003-10-23 WO claimed
US-20030190355-A1 Modified release minerals DRUGTECH CORPORATION 2003-10-09 US claimed
WO-2003042404-A2 BREAST CANCER ERADICATION PROGRAM SIRBASKU DAVID A (US) 2003-05-22 WO claimed
US-20030072812-A1 Breast cancer eradication program SIGNE BIOPHARMA INC. 2003-04-17 US claimed
CN-116768792-B Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2024-10-18 CN disclosed
CN-116768792-A Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2023-09-19 CN disclosed
CN-116636620-A Black egg white peptide composition and application thereof 南昌大学 2023-08-25 CN disclosed
WO-2023119230-A1 COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE L'OREAL (FR) 2023-06-29 WO disclosed
EP-0120669-A2 Hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 EP disclosed
EP-0120670-A1 Iron III complexes of hydroxypyridones, and their pharmaceutical compositions NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-10-03 EP disclosed
EP-0094149-A2 Pharmaceutical compositions containing a complex of iron with N-substituted 3-hydroxypyrid-2-one or -4-one derivatives NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1983-11-16 EP disclosed
EP-0093498-A2 Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1983-11-09 EP disclosed